Bone Biopsy Market Share

Growing demand for minimally invasive procedures is fuelling the growth of the global bone biopsy market. A minimally invasive procedure is the use of a variety of techniques to operate with less damage to the patient’s body. It has various benefits, such as fewer operative and post-operative major complications, less post-operative pain, shortened hospital stays, and faster recovery times. According to the WHO, in 2019, it was reported that around 235 million major surgeries are conducted every year across the globe.

Bone biopsy is a minimally invasive procedure that becomes the initial procedure of choice in most cases for obtaining bone samples. It offers multiple advantages over open surgical biopsy, including minimal soft tissue injury, maintenance of a bone structure, and a reduced need for general anesthesia. This results in an increasing preference for minimally invasive procedures by patients. This is driving the global bone biopsy market

Increasing acceptance of bone marrow biopsy for diagnosis and treatment of lymphoma and leukemia disease

The stringent regulatory policies for manufacturing and distributing medical devices in various regions are hampering the growth of the global bone biopsy market. For instance, the US Food & Drug Administration (FDA)’s Center for Devices and Radiological Health (CDRH) regulates the manufacturing, repackaging, relabelling, and/or importing of medical devices sold in the US. The basic regulatory requirements that manufacturers of medical devices distributed in the U.S. must comply with are established registration, medical device listing, premarket notification 510 (k), quality system regulations, medical device reporting, and others.

Both domestic and foreign manufacturers of medical devices must register their establishments with the FDA. This is a restraining factor for the players involved in the global bone biopsy market.

Improving healthcare infrastructure across emerging countries is creating opportunities for the players involved in the bone biopsy market. The growth of the healthcare infrastructure enhances the development of advanced products for bone biopsy procedures. The players involved in the healthcare sector across emerging countries are heavily investing in technologies. For instance, in May 2022, Terumo India, the Indian arm of Terumo Corporation, signed a partnership agreement with US-based Argon Medical, the market leader in specialty medical products, including guide wires, IVC filters & retrievals, bone & soft tissue biopsy needles, and other products in India.

It will help Terumo to offer advanced medical solutions. The geriatric population is increasing in emerging countries such as China and India. For instance, according to WHO, in 2019, there were 254 million older people aged 60 and over, and 176 million older people aged 65 and over in China. Geriatric people are more susceptible to chronic diseases such as cancer, which is also fuelling the demand for advanced bone biopsy products in the region.

Value Chain Analysis

The global bone biopsy market is showing positive movements in growth owing to the increasing cases of blood and marrow diseases and growing incidences of bone cancer across the globe. The value chain analysis for the market comprises four major components, which start with the R&D designing, manufacturing, distribution & sales, and post-sales review.

Bone biopsy needles and other products related to bone biopsy require extensive research and development to obtain accurate results. The scientific research and development of advanced and effective biopsy products have excelled in diagnosing bone marrow-related diseases among individuals. These products require years of investigation and product testing to get an efficient and accurate portfolio. R&D and designing of such products are focused on expanding their product range of new needles aimed at improving surgical procedures. In this process, the product strategies are ready, and the manufacturing process of the product commences.

The manufacturing process begins with the assembling of raw materials and production of needles, and other products in-house or through third-party manufacturers. Distribution & sales is an essential part of any industry. The revenue of the bone biopsy market majorly depends on distribution and sales. This market consists of distribution & sales, which further includes intermediaries, direct selling, and others. A robust distribution network, strong customer base, and effective sales team drive the sales of bone biopsy consumables.

As products in the market are developed for testing bone marrow problems, the development of abnormal cells and other bone problems are reviewed by government agencies, and their functions are monitored closely to minimize any side effects among the users. The products are also monitored to enhance the current functioning and eliminate the existing problems related to the side effects and other minor glitches.

The Global Bone Biopsy Market Industry is projected to experience substantial growth over the next decade. With an estimated market value of 0.72 USD Billion in 2024, it is expected to reach 1.3 USD Billion by 2035. This growth trajectory indicates a compound annual growth rate (CAGR) of 5.54% from 2025 to 2035. Factors contributing to this growth include increasing incidences of bone disorders, advancements in biopsy technologies, and rising awareness of bone health. These projections suggest a promising future for the industry, driven by both technological and demographic trends.

The Global Bone Biopsy Market Industry is witnessing an expansion in applications, particularly in oncology. Bone biopsies are increasingly utilized for diagnosing metastatic cancers and assessing treatment responses. As the global cancer burden rises, the need for accurate diagnostic tools becomes more critical. For example, bone metastases occur in approximately 70% of patients with advanced breast or prostate cancer, necessitating effective biopsy procedures. This trend indicates a growing market potential, as healthcare providers seek reliable methods for cancer diagnosis and management, further driving the industry's growth.

Government initiatives aimed at improving healthcare infrastructure and funding for diagnostic procedures are positively influencing the Global Bone Biopsy Market Industry. Various countries are investing in healthcare systems to enhance access to advanced diagnostic tools, including bone biopsies. For instance, national health programs that allocate funds for cancer diagnosis and treatment are likely to increase the availability of bone biopsy services. This support from governments may lead to a more robust market environment, facilitating growth and innovation within the industry.

The Global Bone Biopsy Market Industry is experiencing growth driven by the rising prevalence of bone disorders such as osteoporosis and bone cancers. As populations age, the incidence of these conditions increases, necessitating diagnostic procedures like bone biopsies. For instance, osteoporosis affects approximately 200 million women worldwide, highlighting the need for effective diagnostic tools. This trend is expected to contribute to the market's expansion, with the industry projected to reach 0.72 USD Billion in 2024, indicating a growing demand for bone biopsy procedures.

Growing awareness regarding bone health and the importance of early diagnosis is propelling the Global Bone Biopsy Market Industry. Public health initiatives and screening programs aimed at detecting bone-related diseases are becoming more prevalent. For instance, campaigns promoting osteoporosis screening have led to increased patient referrals for bone biopsies. This heightened awareness is likely to drive demand for diagnostic procedures, contributing to the market's growth trajectory. By 2035, the industry is projected to reach 1.3 USD Billion, underscoring the impact of awareness on the adoption of bone biopsy techniques.

Innovations in biopsy techniques are significantly influencing the Global Bone Biopsy Market Industry. The introduction of minimally invasive procedures and advanced imaging technologies enhances the accuracy and safety of bone biopsies. For example, the use of ultrasound-guided biopsies allows for real-time imaging, improving the precision of needle placement. These advancements not only improve patient outcomes but also increase the efficiency of the procedures, potentially leading to a higher adoption rate. As a result, the market is anticipated to grow at a CAGR of 5.54% from 2025 to 2035, reflecting the positive impact of technology on the industry.